Lucozole T Cream

Dermatomycoses caused by zoophilic strains, particularly Trichophyton mentagrophytes, are becoming increasingly challenging to treat due to the emergence of terbinafine-resistant strains. These resistances are largely attributed to mutations in the squalene epoxidase (SQLE) gene, the target site of terbinafine. As a result, there is a growing demand for alternative antifungal treatments.

Study Objective
To evaluate the in vivo therapeutic efficacy of luliconazole 1% cream compared to terbinafine 1% cream in treating infections caused by T. mentagrophytes, and to assess their antifungal activity through in vitro susceptibility testing.

Methods
Patients were evaluated using:

KOH with DMSO direct microscopy

qPCR with pan-dermatophyte primers

Fungal culture

Additionally, in vitro minimum inhibitory concentrations (MICs) were determined for both luliconazole and terbinafine.

Key Findings

Luliconazole showed significantly superior antifungal efficacy.

MIC (Geometric Mean):

• Luliconazole: 0.002 μg/ml
• Terbinafine: 0.004 μg/ml

A 28-day course of topical luliconazole achieved complete clinical and microbiological cure in all patients, with full eradication of the pathogen.

Conclusion
With the rising incidence of terbinafine-resistant T. mentagrophytes infections, luliconazole 1% cream emerges as an effective and reliable topical antifungal alternative. Its superior potency and high eradication rate underscore its value in the management of difficult-to-treat zoophilic dermatomycoses.